Last reviewed · How we verify
NCT06894953: AMPER
AMPER Proof of Concept Study
NA trial testing Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER) in Alzheimer's Dementia (AD) in 40 participants. Not yet recruiting.
28 February 2026
Quick facts
| Lead sponsor | University of Strathclyde |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 1 April 2025 |
| Primary completion | 28 February 2026 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)
- Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)
Conditions studied
- Alzheimer's Dementia (AD) — all drugs for Alzheimer's Dementia (AD) →
Sponsor
University of Strathclyde
Who can join
50 and older, any sex, with Alzheimer's Dementia (AD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The AMPER (Agent-based Memory Prosthesis to Encourage Reminiscing) system has been built to help people with Alzheimer's disease by improving their memory recall and quality of life. Alzheimer's often leads to the loss of autobiographical memories, which can affect a person's sense of identity. AMPER seeks to address this by creating a digital memory aid that uses an engaging, animated character on a tablet to help individuals with Alzheimer's reminisce about their past. By presenting personally relevant stories, images, audio, and videos, the character helps trigger memories and encourages interaction with caregivers. This is proof of concept study using a randomised controlled trial methodology. Twenty participants will be randomised to the control and 20 randomised to the intervention condition. The intervention group will use a personalised version of the AMPER app with tailored content and the control group will use a non-personalised version without specific adaptations. Over 12 weeks, participants will use the app at home with their caregivers. Researchers will measure changes in their memory and cognitive abilities before and after these 12 weeks. The primary goal is to see if personalised reminiscence improves the perceived quality of the reminiscence experience and autobiographical memory ability compared to the same app with a non-personalised approach. This will be measured using a combination of automatically gathered app use data and weekly caregiver feedback. Secondary goals are to investigate any difference between participants in the intervention and control condition in their technology acceptance, quality of life, self-esteem, everyday functioning and cognitive ability. Feedback from this research will help refine AMPER and inform future studies, with the ultimate goal of creating a widely accessible tool that supports memory and well-being in Alzheimer's patients. Table 1 provides a summary of the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06894953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Strathclyde trials
Trials by the same sponsor.
- NCT06806748 — Gait Recovery After Stroke · not yet recruiting
- NCT06928285 — Community Rollout of Technology Enriched Rehabilitation After Stroke: An Implementation Study · NA · not yet recruiting
- NCT06419062 — The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 2 · enrolling by invitation
- NCT06419036 — The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1 · enrolling by invitation
- NCT06294041 — INvestigating the Value of Early Sleep Therapy · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06894953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Strathclyde
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06894953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing